Dramatic dip in baby hospitalizations for RSV linked to vaccine and treatment
GuardianMAY 17
Safety concerns remain a significant consideration in maternal RSV vaccination programs. One vaccine candidate showed a 37% increase in preterm birth rates, highlighting the need for enhanced monitoring and careful risk-benefit analysis. The challenge of developing new vaccines while maintaining competitive advantage and managing public perception creates additional barriers to advancing RSV prevention options.